Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$60.67 - $89.12 $348,306 - $511,637
5,741 Added 35.77%
21,790 $1.49 Million
Q4 2023

Feb 14, 2024

BUY
$38.62 - $72.18 $619,812 - $1.16 Million
16,049 New
16,049 $1 Million
Q2 2023

Aug 14, 2023

BUY
$43.47 - $67.77 $1.11 Million - $1.73 Million
25,562 New
25,562 $1.44 Million
Q4 2022

Feb 14, 2023

BUY
$39.19 - $65.67 $41,384 - $69,347
1,056 Added 4.42%
24,949 $1.01 Million
Q3 2022

Nov 14, 2022

BUY
$61.1 - $83.78 $257,292 - $352,797
4,211 Added 21.4%
23,893 $1.56 Million
Q2 2022

Aug 15, 2022

SELL
$43.23 - $73.83 $229,162 - $391,372
-5,301 Reduced 21.22%
19,682 $1.2 Million
Q1 2022

May 16, 2022

SELL
$53.19 - $79.24 $212 - $316
-4 Reduced 0.02%
24,983 $1.57 Million
Q4 2021

Feb 14, 2022

BUY
$70.09 - $111.29 $259,403 - $411,884
3,701 Added 17.39%
24,987 $1.89 Million
Q3 2021

Nov 15, 2021

BUY
$110.2 - $156.64 $2.35 Million - $3.33 Million
21,286 New
21,286 $2.38 Million
Q1 2021

May 17, 2021

SELL
$110.72 - $210.04 $1.75 Million - $3.33 Million
-15,841 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$79.67 - $173.23 $705,716 - $1.53 Million
8,858 Added 126.85%
15,841 $2.43 Million
Q3 2020

Nov 16, 2020

BUY
$78.5 - $100.64 $150,406 - $192,826
1,916 Added 37.81%
6,983 $584,000
Q2 2020

Aug 14, 2020

SELL
$38.5 - $76.05 $238,007 - $470,141
-6,182 Reduced 54.96%
5,067 $372,000
Q1 2020

May 15, 2020

SELL
$33.68 - $62.53 $184,701 - $342,914
-5,484 Reduced 32.77%
11,249 $477,000
Q4 2019

Feb 14, 2020

BUY
$36.68 - $73.13 $613,766 - $1.22 Million
16,733 New
16,733 $1.02 Million
Q2 2018

Aug 14, 2018

SELL
$42.62 - $73.59 $366,872 - $633,462
-8,608 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$23.52 - $58.17 $202,460 - $500,727
8,608 New
8,608 $393,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $4.03B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.